United Therapeutics | UTHR - Equity Capital And Reserves


United Therapeutics reported $6.59B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Amarin USD 458.89M 6.03M Sep/2025
Ardelyx USD 154.28M 14.75M Sep/2025
Baxter International USD 6.13B 1.11B Dec/2025
Bayer EUR 29.7B 799M Sep/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Biogen USD 18.21B 573.5M Sep/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Emergent BioSolutions USD 649.3M 47.9M Dec/2023
Esperion Therapeutics USD -451.36M 17.85M Sep/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Halozyme Therapeutics USD 48.81M 455.1M Dec/2025
Insmed USD 738.98M 206.6M Dec/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
J&J USD 78.47B 0 Sep/2025
Lexicon Pharmaceuticals USD 129.44M 6.41M Jun/2025
Moderna USD 8.65B 680M Dec/2025
Omeros USD -228.68M 15.13M Jun/2025
Pfizer USD 92.8B 4.11B Sep/2025
PTC Therapeutics USD -205.31M 49.56M Dec/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Teva Pharmaceutical Industries USD 7.91B 664M Dec/2025
United Therapeutics USD 6.59B 583.4M Sep/2025
Vertex Pharmaceuticals USD 18.67B 1.35B Dec/2025